Results 41 to 50 of about 12,875 (237)
Mechanical Flexibility Enables DNA Origami to Overcome Steric Confinement in Mucus
Advanced Science, EarlyView.Mechanical flexibility is introduced as a design parameter to enhance nanocarrier transport in mucus. Using DNA origami, flexibility is decoupled from size, shap and surface chemistry, revealing improved passage through confined hydrogel networks. While surface passivation reduces aggregation, flexibility further boosts transport, offering a general ...
Matteo Tollemeto +5 more
wiley +1 more source
Scientific ReportsThis study compared efficacy and safety of lipegfilgrastim with filgrastim in pediatric patients. Children and adolescents receiving chemotherapy (4 cycles) for Ewing sarcoma or rhabdomyosarcoma were randomized 1:1 to lipegfilgrastim (100 µg/kg) once per
Margarita B. Belogurova +4 more
doaj +1 more source
Pharmacological Research, 2019 Biotechnologicals are an invaluable resource in the treatment of patients with inflammatory rheumatic diseases (IRD) non-responsive or intolerant to conventional therapies. However, they are the main driver for increase in direct costs and represent a significant economic burden to healthcare systems worldwide.
Araújo, Filipe C. +2 more
openaire +3 more sources
Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
INNOVATIONS in PharmacyBiosimilars are safe and effective treatments for chronic diseases such as cancer and rheumatoid arthritis. The Saudi Food and Drug Authority (SFDA) manages the quality and registration of biosimilars in the Kingdom of Saudi Arabia.
Mohammed Alqahtani +2 more
doaj +1 more source
ESMO Open, 2018 Biosimilars will soon become broadly available in the oncology field, raising important questions from both patients and healthcare providers. These questions need to be clarified upfront, in order to increase confidence in using these therapies. In this podcast, Teresa Amaral (Young Oncologist Committee member) talks to Josep Tabernero (ESMO President
openaire +3 more sources
Biosimilar: what it is not [PDF]
British Journal of Clinical Pharmacology, 2015 A biosimilar is a high quality biological medicine shown to be in essence the same as an original product. The European Medicines Agency (EMA) paved the way in the regulatory arena by creating a safeguarding framework for the development of biosimilars.
openaire +2 more sources
The biosimilars journey: current status and ongoing challenges
, 2018 Biosimilar products are already approved and marketed in several countries. The Food and Drug Administration has approved ten different biosimilars, and the European Medicines Agency has approved 40.
Daniel Egg Neto +3 more
core +1 more source
Bulletin of Faculty of Pharmacy Cairo UniversityBackground: Biologics have provided enhanced clinical advantages, but at expense of enormous expenditures. The exorbitant expense of biologics was somewhat mitigated by the development of biosimilars.
Doaa M. Abd-El-Rady +2 more
doaj +1 more source
Annals of Oncology, 2008 The purpose of this report was to review issues associated with the introduction of alternative versions of biosimilars used in the oncology setting.Data were obtained by searches of MEDLINE, PubMed, references from relevant English-language articles, and guidelines from the European Medicines Agency.When biosimilars are approved in EU, they will be ...
H, Mellstedt, D, Niederwieser, H, Ludwig
openaire +2 more sources
Understanding and Incentivizing Biosimilars [PDF]
, 2012 Congress recently passed the Biosimilars Act in an attempt to replicate the success that generic small molecule drugs have enjoyed under the Hatch-Waxman Act.
Feldman, Robin, Kanter, Jason
core +3 more sources